The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective

Area of Science:

• Microbiology and Drug Discovery
• Mycobacterial Cell Wall Biosynthesis

Background:

• The Mycobacterium tuberculosis cell wall is a complex, layered structure providing a protective shield.
• Existing anti-tuberculosis drugs, such as isoniazid and ethambutol, target enzymes involved in cell wall synthesis.
• The unique composition of the mycobacterial cell wall presents numerous enzymatic targets for therapeutic intervention.

Purpose of the Study:

• To systematically review enzymes in the mycobacterial cell wall biosynthesis pathway as potential drug targets.
• To highlight current drug development strategies focusing on inhibiting key enzymes like DprE1, InhA, and MmpL3.
• To provide a perspective on developing novel anti-TB agents targeting cell wall synthesis.

Main Methods:

• Systematic review of scientific literature on Mycobacterium tuberculosis cell wall synthesis.
• Analysis of enzymes involved in peptidoglycan, arabinogalactan, and mycolic acid biosynthesis.
• Identification of druggable targets currently being explored in anti-TB drug development.

Main Results:

• Several enzymes in the cell wall biosynthesis pathway are validated targets for anti-TB drugs.
• Key targets like DprE1, InhA, and MmpL3 are central to current drug discovery efforts.
• A significant number of anti-TB agents in clinical trials are designed to inhibit cell wall synthesis.

Conclusions:

• Targeting enzymes in the Mycobacterium cell wall biosynthesis pathway is a promising strategy for developing new anti-TB drugs.
• Further research into these targets could lead to effective treatments against Mtb infection.
• The systematic exploration of cell wall synthesis inhibitors offers a viable path for combating tuberculosis.